TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
In a population of kidney transplant recipients having developed a first squamous cell
carcinoma, the aim of the study is to assess the incidence of subsequent skin cancers over 2
years in patients who are switched to rapamycin as compared to patients who are maintained
under calcineurin inhibitors.